Fortis Healthcare Ltd's Q2 FY27 numbers came in mixed, with revenue of Rs. 2,734.83 Cr (+17.30% YoY) and PAT growth of -2.54% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | November 05, 2026 |
|---|---|
| Revenue (Q2) | Rs. 2,734.83 Cr (+17.30% YoY) |
| PAT (Q2) | Rs. 320.47 Cr (-2.54% YoY) |
| EBITDA margin | 23.03% (-180 bps YoY) |
| EPS (Q2) | Rs. 4.14 (-2.82% YoY) |
Revenue grew 17.30% YoY with Healthcare at +18.56% tracking the 15%+ guidance and Diagnostics at +12.16% within its 12-13% band, while EBITDA margin expanded 136 bps sequentially to 23.03%. Reported PAT declined 2.54% YoY due to the ESOP charge (~Rs.40 Cr), a higher 25.87% tax rate and lower other income, and receivables grew 26.75% since March with doubtful-debt charges doubling to Rs.52.16 Cr in H1. Cash conversion at 1.27x CFO/PAT and net debt reduction of Rs.101.55 Cr support balance-sheet quality, with the ex-ESOP margin guidance leg still unverified from the filing.
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.